Triomics nabs $22M to bring oncology-specific AI to cancer centers
techcrunch.com May 28, 2026

Triomics nabs $22M to bring oncology-specific AI to cancer centers

AI-summarised brief · reviewed before publication

Triomics, a startup developing an AI-powered platform for oncology, has secured $22 million in Series B funding led by Battery Ventures. The platform helps oncologists and administrative staff automate data-heavy tasks, such as clinical trial matching and appointment prep, by reducing the time spent reviewing complex medical records. Founded in 2021, Triomics has expanded its platform to include verifiable patient summaries and is used by prominent institutions like Memorial Sloan Kettering and Yale Cancer Center. The startup has seen significant growth, expanding its enterprise customer base fourfold and increasing annualized recurring revenue 10-fold.

💡 Why It Matters

  • · The growing complexity of medical records is a significant challenge for oncology, where patient histories are unusually complex and staff burnout is a persistent problem.
  • · By reducing administrative load, tools like Triomics can have an outsized impact on the efficiency of cancer centers, allowing oncologists to spend more time with patients and potentially improving patient outcomes.